Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 8;3(3):210–216. doi: 10.1002/jgh3.12139

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

One‐way sensitivity analysis showing all parameters contributing to hepatitis C virus treatment cost. (), Weekly cost of direct‐acting antiviral (DAA) (3847.0–11 628.0); (), probability of sustained virological response (SVR) with pegylated interferon and ribavirin (PR) at week 24 (0.67–0.84); (), utility of chronic hepatitis C infection (0.84–1.0); (), weekly cost of outpatient visits while on PR (6.9–345.0); (), disutility associated with using PR (0.091–0.121); (), weekly cost of hospitalization while on PR (0.0–281.4); (), disutility of treatment failure (0.06–0.16); (), utility of SVR (0.92–1.0); (), weekly cost of Pegylated interferon + ribavirin (429.5–642.8); (), probability of SVR with DAA at week 12 (0.93–0.98); (), weekly cost of hospitalization while on DAA (0.0–396.5); (), weekly cost of emergency department (ED) visit while on DAA (0.0–243.2); (), weekly cost of outpatient visits while on DAA (61.2–299.2); (), weekly cost of erythropoietin while on PR (0.0–21.3); (), weekly cost of filgrastim while on PR (0.0–19.6); (), probability of SVR with DAA at week 36 (0.84–0.91); (), weekly cost of ED visit while on PR (0.0–55.0); (), probability of SVR with DAA at week 24 (0.95–0.96).

Inline graphic — One‐way sensitivity analysis showing all parameters contributing to hepatitis C virus treatment cost. (), Weekly cost of direct‐acting antiviral (DAA) (3847.0–11 628.0); (), probability of sustained virological response (SVR) with pegylated interferon and ribavirin (PR) at week 24 (0.67–0.84); (), utility of chronic hepatitis C infection (0.84–1.0); (), weekly cost of outpatient visits while on PR (6.9–345.0); (), disutility associated with using PR (0.091–0.121); (), weekly cost of hospitalization while on PR (0.0–281.4); (), disutility of treatment failure (0.06–0.16); (), utility of SVR (0.92–1.0); (), weekly cost of Pegylated interferon + ribavirin (429.5–642.8); (), probability of SVR with DAA at week 12 (0.93–0.98); (), weekly cost of hospitalization while on DAA (0.0–396.5); (), weekly cost of emergency department (ED) visit while on DAA (0.0–243.2); (), weekly cost of outpatient visits while on DAA (61.2–299.2); (), weekly cost of erythropoietin while on PR (0.0–21.3); (), weekly cost of filgrastim while on PR (0.0–19.6); (), probability of SVR with DAA at week 36 (0.84–0.91); (), weekly cost of ED visit while on PR (0.0–55.0); (), probability of SVR with DAA at week 24 (0.95–0.96).